Viral Gastroenteritis Market is Expected to Grow at a CAGR over 4.40% by 2030

Pune, India, 2022 /MRFR Press Release/- Market Research Future has a half cooked research report on the global viral gastroenteritis market.

Market Highlights

Viral gastroenteritis is one of the common gastrointestinal disease across the globe. It is a communicable disease transmitted through contaminated food or water and direct contact with the infected person. Notovirus is the common cause of viral gastritis in various developed and developing countries across the globe.

Rising prevalence of gastrointestinal disease across the globe, demand for new drugs for the treatment and increasing expenses on research and development in gastroenterology fuel the market growth. Additionally, the growing concerns about the spread of the disease among children and an urgent need to manage viral gastroenteritis also contribute to the market growth.

Fierce competition among key market players acts as a barrier for the new entrant in the market.

The Viral Gastroenteritis Market is expected to reach USD 6,4772.93 Million by 2030 at 4.40% CAGR during the forecast period 2022-2030

Taste the market data and market information presented through more than 120 market data tables and figures spread over 206 pages of the project report. Avail the in-depth table of content (TOC) & market synopsis on “Viral gastroenteritis market research report–Global forecast till 2030.”

Major Players in Viral gastroenteritis Market

Some of the key players in the global market are Valeant Pharmaceuticals (U.S.), Janssen Global Services, LLC (U.S.), Takeda Pharmaceutical (Japan), Bayer AG (Germany), Sanofi (France), Allergan (Ireland), GlaxoSmithKline (U.S.), Abbott (U.S.),  and AstraZeneca (U.K).

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Viral Gastroenteritis Market Research Report

Regional Analysis

America is the largest market for viral gastroenteritis owing to rising prevalence of viral gastroenteritis in the U.S., especially among the pediatric population. According to the Center for Disease Control and Prevention (CDC), each year in the United States, there are nearly 19 to 21 million cases of acute gastroenteritis. Furthermore the prevalence of acute gastrointestinal diseases is found to be high in Canada.

Europe is the second largest market for viral gastroenteritis. According to an article published in the journal of Clinical Virology, in Europe, acute infectious gastroenteritis is one of the major causes for substantial morbidity and economic loss.

In Asia Pacific, increasing prevalence of communicable diseases, rising geriatric population with chronic diseases, and demand for new diagnosis and treatment methods drive the market growth. This region, the common is rotavirus cause of severe gastroenteritis in children less than 5 years of age. In China and India, the extensive research and development activities have speeded up from last few years.

The Middle East & Africa also shows a steady rise in the market owing to increasing number of cases of diarrhea due to viral infection. 

Segmentation

The global viral gastroenteritis market is segmented on the basis of type of virus, diagnosis, drugs, indication, and end user.

On the basis of type of virus, market is segmented into norovirus, rotavirus, astrovirus, and enteric adenovirus.

On the basis of diagnosis, the market is segmented into physical examination and rapid stool test.

On the basis of drugs, the market is segmented into Antibiotics, antacids, laxatives, antimotility agents and others. Other drugs are antiemetics and chemotherapy drugs.

On the basis of indication, the market is segmented into watery diarrhea, vomiting, abdominal cramps and pain and others.

On the basis of end user, the market is segmented into hospitals, clinics, pharmaceutical companies, diagnostic centers, ambulatory care centers and others.